Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

FDA rejects Takeda’s Eohilia after delays

After more than a year on ‘priority review’, the FDA has said it cannot approve Takeda’s budesonide oral suspension without a further clinical study

- PMLiVE

FDA approves Amgen’s Otezla for all patients with plaque psoriasis

The FDA has expanded use of Otezla to adults with mild to moderate plaque psoriasis, making it the first oral treatment for the skin condition, regardless of severity

- PMLiVE

Sanofi to pay $1.2bn to acquire Amunix and its ‘stealth’ technology

Sanofi will acquire Amunix’s next-generation protein engineering tech that allows biologic drugs to circulate in ‘stealth’ mode, becoming active only in diseased tissues

Research Partnership is on the rise

Research Partnership ranks 12th in fastest growing UK market research agency league  tables

Inizio

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

- PMLiVE

AstraZeneca’s Saphnelo to be approved in Europe for lupus

The EMA is set to approve the first new treatment for systemic lupus erythematosus in Europe in more than a decade

- PMLiVE

The Communiqué Awards welcome Fiona McMillan and Jeremy Clark as the new co-chairs of the judging panel

The previous co-chairs Louise Dunn and Annabelle Sandeman have stepped down after three years

- PMLiVE

Can tobacco companies really reinvent themselves as healthcare companies?

A surprising move by key player, Phillip Morris, has called attention to the start of a new era for the tobacco industry. But can tobacco companies reinvent themselves as healthcare...

Say Communications

- PMLiVE

Tezspire approved in US for severe asthma

AstraZeneca and Amgen’s monoclonal antibody Tezspire is now available to control dangerous exacerbations in all adults and children aged 12 years and above with severe asthma

- PMLiVE

US prefers mRNA COVID-19 vaccines over J&J

Citing concerns over blood clots, Americans are now advised that should get the Pfizer-BioNTech or Moderna vaccines in preference to Johnson and Johnson vaccine

- PMLiVE

Emergency use of Paxlovid allowed in Europe

The EMA has issued advice to member states on potentially pre-approval use of Pfizer’s anti-COVID-19 treatment Paxlovid while a rolling review of data is ongoing

Biogen Idec building

Five years needed to confirm the benefit of Aduhelm

Biogen and Eisai have announced plans for a global, phase 3 clinical trial to confirm the long-term clinical benefit of Aduhelm treatment against Alzheimer’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links